Why Citius Oncology, Inc.’s (CTOR) Stock Is Up 6.90%
As of Friday, November 06, Citius Oncology, Inc.’s CTOR share price has surged by 6.90%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Biosciences, Inc.
Commentary & Analysis
Why Citius Oncology, Inc.’s (CTOR) Stock Is Up 8.13%
As of Wednesday, November 04, Citius Oncology, Inc.’s CTOR share price has surged by 8.13%, which has investors questioning if this is right time to sell.Michael Rose
Why Citius Oncology, Inc.’s (CTOR) Stock Is Up 9.21%
As of Monday, November 02, Citius Oncology, Inc.’s CTOR share price has surged by 9.21%, which has investors questioning if this is right time to sell.Michael Rose
Why Citius Oncology, Inc.’s (CTOR) Stock Is Down 5.21%
As of Friday, October 30, Citius Oncology, Inc.’s CTOR share price has dipped by 5.21%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Citius Oncology, Inc.’s (CTOR) Stock Is Down 11.04%
As of Thursday, October 29, Citius Oncology, Inc.’s CTOR share price has dipped by 11.04%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | CTOR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $53.9 | $219.9 | 17% |
|
| Shares Out (Mil) | 107.9 | 54.1 | 63% |
|
| Institutional Ownership | 99.6% | 92.9% | 90% |
|
| Float (Mil) | 31.0 | 41.4 | 37% |
|
| Beta | 3.53 | 0.95 | 98% |
|
| Avg Daily Volume (000s) | 259 | 522 | 48% |
|
| Price Change (52-week) |
(66.9%) | 44.7% | 13% |
|
| Growth | CTOR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | CTOR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $7 | $38 | 7% |
|
| Net Income (TTM) (Mil) | ($46) | ($44) | 17% |
|
| EPS (TTM) | ($0.493) | ($1.500) | 27% |
|
| Operating Cash Flow (TTM) (Mil) | ($19) | ($35) | 15% |
|
| Net Cash Flow (TTM) (Mil) | $17 | $0 | 61% |
|
| Long-Term Debt (Q1) (Mil) | $10 | $4 | 29% |
|
| Enterprise Value (Q1) (Mil) | $102 | $166 | 21% |
|
| Valuation | CTOR | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.34 | 2.06 | 38% |
|
| P/E | na | 16.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | CTOR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 74.8% | 67.3% | 85% |
|
| Net Margin | (648.3%) | (61.0%) | 1% |
|
| ROA | (45.2%) | (47.5%) | 12% |
|
| ROE | (126.6%) | (52.7%) | 7% |
|
| Liabilities to Assets | 64.0% | 29.6% | 59% |
|
| F-Score | 2 | 3 | 7% |
|
Citius Oncology, Inc. did not pass any screens on 11/6/2026.
